dapsone has been researched along with Scleroderma, Systemic in 2 studies
Scleroderma, Systemic: A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| WUERTHELE, V | 1 |
| May, DG | 1 |
| Black, CM | 1 |
| Olsen, NJ | 1 |
| Csuka, ME | 1 |
| Tanner, SB | 1 |
| Bellino, L | 1 |
| Porter, JA | 1 |
| Wilkinson, GR | 1 |
| Branch, RA | 1 |
2 other studies available for dapsone and Scleroderma, Systemic
| Article | Year |
|---|---|
Scleroderma treated with promin, with report of a case.
Topics: Dapsone; Scleroderma, Systemic | 1947 |
Scleroderma is associated with differences in individual routes of drug metabolism: a study with dapsone, debrisoquin, and mephenytoin.
Topics: Acetylation; Adult; Biotransformation; Dapsone; Debrisoquin; Disease Susceptibility; Female; Humans; | 1990 |